

# Santiago Perez-Lloret

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1949874/santiago-perez-lloret-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

3,695  
citations

31  
h-index

57  
g-index

140  
ext. papers

4,402  
ext. citations

4.2  
avg. IF

5.46  
L-index

#	Paper	IF	Citations
123	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26 Suppl 3, S42-80	7	599
122	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , <b>2019</b> , 34, 180-198	7	357
121	Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. <i>JAMA Neurology</i> , <b>2014</b> , 71, 884-90	17.2	159
120	Sleep disordered breathing and daytime sleepiness are associated with poor academic performance in teenagers. A study using the Pediatric Daytime Sleepiness Scale (PDSS). <i>Sleep</i> , <b>2007</b> , 30, 1698-703	1.1	114
119	Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. <i>Movement Disorders</i> , <b>2011</b> , 26, 2226-31	7	99
118	Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2016</b> , 2, 16001	9.7	93
117	Autosomal dominant cerebellar ataxias: a systematic review of clinical features. <i>European Journal of Neurology</i> , <b>2014</b> , 21, 607-15	6	90
116	Decision-making in Parkinson's disease patients with and without pathological gambling. <i>European Journal of Neurology</i> , <b>2010</b> , 17, 97-102	6	88
115	New treatments for levodopa-induced motor complications. <i>Movement Disorders</i> , <b>2015</b> , 30, 1451-60	7	82
114	Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. <i>CNS Drugs</i> , <b>2010</b> , 24, 941-68	6.7	79
113	Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150621	3.7	68
112	Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2012</b> , 35, 261-5	1.4	64
111	Addenbrooke's Cognitive Examination validation in Parkinson's disease. <i>European Journal of Neurology</i> , <b>2009</b> , 16, 142-7	6	63
110	Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 107-11	7	59
109	Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. <i>European Journal of Pain</i> , <b>2016</b> , 20, 151-65	3.7	58
108	Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. <i>European Journal of Neurology</i> , <b>2012</b> , 19, 28-37	6	57
107	A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. <i>Journal of Pineal Research</i> , <b>2002</b> , 32, 41-6	10.4	54

106	A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance: an exploratory cross-sectional study in teenagers. <i>Journal of Clinical Sleep Medicine</i> , <b>2013</b> , 9, 469-73	3.1	53
105	Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18, 501-5	3.6	42
104	A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. <i>Neuroendocrinology Letters</i> , <b>2002</b> , 23, 55-60	0.3	42
103	Falls in ambulatory non-demented patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 1447-55	4.3	41
102	Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 1237-1250	4.3	41
101	Rotigotine transdermal delivery for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 677-91	4	37
100	Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1323-9	3.6	35
99	Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18, 358-61	3.6	35
98	L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 1532-1538	6	33
97	Management of constipation in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 547-57		32
96	Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. <i>Endocrine</i> , <b>2003</b> , 22, 245-8		32
95	Trends in inpatient antiparkinson drug use in the USA, 2001-2012. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1011-9	2.8	31
94	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 351-60	4.1	31
93	Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping. <i>International Journal of Cardiology</i> , <b>2008</b> , 127, 387-9	3.2	31
92	New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 554-61	5.5	30
91	Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. <i>Journal of Neurology</i> , <b>2009</b> , 256, 1480-4	5.5	30
90	A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 310, 248-50	3.2	29
89	Gender-related differences in urinary 6-sulfatoxymelatonin levels in obese pubertal individuals. <i>Journal of Pineal Research</i> , <b>2006</b> , 40, 214-8	10.4	29

88	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. <i>CNS Drugs</i> , <b>2016</b> , 30, 703-17	6.7	28
87	Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , <b>2014</b> , 1, 154-160	2.2	28
86	Emerging analgesic drugs for Parkinson's disease. <i>Expert Opinion on Emerging Drugs</i> , <b>2012</b> , 17, 157-71	3.7	27
85	Heart rate nonlinear dynamics during sudden hypoxia at 8230 m simulated altitude. <i>Wilderness and Environmental Medicine</i> , <b>2010</b> , 21, 4-10	1.4	27
84	Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. <i>Cellular and Molecular Neurobiology</i> , <b>2002</b> , 22, 699-709	4.6	27
83	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 527-537	2.2	27
82	Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1163-1173	5.9	24
81	RBD-specific polyclonal F(ab $\gamma$ ) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. <i>EClinicalMedicine</i> , <b>2021</b> , 34, 100843	11.3	23
80	Emerging drugs for autonomic dysfunction in Parkinson's disease. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 39-53	3.7	22
79	Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 824-7	1.7	22
78	Sleep habits, alertness, cortisol levels, and cardiac autonomic activity in short-distance bus drivers: differences between morning and afternoon shifts. <i>Journal of Occupational and Environmental Medicine</i> , <b>2011</b> , 53, 806-11	2	21
77	Safety of rasagiline for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 633-43	4.1	21
76	Cerebroventricular administration of interferon-gamma modifies locomotor activity in the golden hamster. <i>NeuroSignals</i> , <b>2003</b> , 12, 89-94	1.9	21
75	Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1097-107	4	20
74	Effects of different "relaxing" music styles on the autonomic nervous system. <i>Noise and Health</i> , <b>2014</b> , 16, 279-84	0.9	19
73	Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. <i>Movement Disorders</i> , <b>2010</b> , 25, 1876-80	7	19
72	Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2006</b> , 77, 172-4	5.5	19
71	A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , <b>2012</b> , 26, 557-64	3.1	18

70	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , <b>2013</b> , 27, 81-95	3.1	17
69	The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2016</b> , 16, 245-58	4.3	16
68	Do Parkinson's disease patients disclose their adverse events spontaneously?. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 857-65	2.8	16
67	Pramipexole for the treatment of early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2011</b> , 11, 925-35	4.3	16
66	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , <b>2021</b> , 36, 283-297	7	16
65	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , <b>2015</b> , 2, 6-16	2.2	15
64	Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2405-2415	4	15
63	Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy. <i>International Journal of Neuroscience</i> , <b>2010</b> , 120, 11-6	2	15
62	Pregabalin-induced parkinsonism: a case report. <i>Clinical Neuropharmacology</i> , <b>2009</b> , 32, 353-4	1.4	15
61	Disruption of ultradian and circadian rhythms of blood pressure in nondipper hypertensive patients. <i>Hypertension</i> , <b>2004</b> , 44, 311-5	8.5	15
60	Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1275-9	7	14
59	Attitudes towards treatment among patients suffering from sleep disorders. A Latin American survey. <i>BMC Family Practice</i> , <b>2003</b> , 4, 17	2.6	13
58	Role of Astrocytic Dysfunction in the Pathogenesis of Parkinson's Disease Animal Models from a Molecular Signaling Perspective. <i>Neural Plasticity</i> , <b>2020</b> , 2020, 1859431	3.3	12
57	Actigraphic evaluation of motor fluctuations in patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , <b>2010</b> , 120, 137-43	2	12
56	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). <i>Parkinsonism and Related Disorders</i> , <b>2008</b> , 14, 641-5	3.6	12
55	Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 650597	5.6	12
54	Sleep disruption in medicine students and its relationship with impaired academic performance: A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , <b>2020</b> , 53, 101333	10.2	11
53	Blunting of circadian rhythms and increased acrophase variability in sleep-time hypertensive subjects. <i>Chronobiology International</i> , <b>2008</b> , 25, 99-113	3.6	11

52	Melatonin treatment counteracts the hyperthermic effect of lipopolysaccharide injection in the Syrian hamster. <i>Neuroscience Letters</i> , <b>2005</b> , 389, 169-72	3.3	11
51	The Parkinson disease pain classification system: results from an international mechanism-based classification approach. <i>Pain</i> , <b>2021</b> , 162, 1201-1210	8	11
50	Melatonin in sleep disorders and jet-lag. <i>Neuroendocrinology Letters</i> , <b>2002</b> , 23 Suppl 1, 9-13	0.3	11
49	Comparison of Olfactory Identification Patterns among Parkinson's Disease Patients from Different Countries. <i>Chemical Senses</i> , <b>2016</b> , 41, 77-83	4.8	9
48	Irritability, psychomotor agitation and progressive insomnia induced by bilateral stimulation of the area surrounding the dorsal subthalamic nucleus (zona incerta) in Parkinson's disease patients. <i>Journal of Neurology</i> , <b>2009</b> , 256, 2091-3	5.5	9
47	Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. <i>Clinical Neuropharmacology</i> , <b>2012</b> , 35, 21-4	1.4	9
46	A cross-sectional study on drug use in multiple system atrophy. <i>CNS Drugs</i> , <b>2014</b> , 28, 483-90	6.7	8
45	Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study. <i>Parkinson's Disease</i> , <b>2011</b> , 2011, 473579	2.6	8
44	Infradian awake and asleep systolic and diastolic blood pressure rhythms in humans. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 1273-9	1.9	8
43	Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease. <i>Clinical Autonomic Research</i> , <b>2020</b> , 30, 265-271	4.3	8
42	Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2221-30	4	7
41	Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. <i>Drugs and Aging</i> , <b>2020</b> , 37, 215-223	4.7	7
40	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 635-645	4	6
39	Therapeutic strategies for Parkinson's disease: promising agents in early clinical development. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 1249-1267	5.9	6
38	Test-retest reliability of the Friedreich's ataxia rating scale. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 1708-1712	5.3	6
37	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , <b>2021</b> , 11, 9611	4.9	6
36	Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 257-267	2.2	6
35	State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 445-457	4	5

34	A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m (Dralitem vs. Temodal Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions. <i>Drugs in R and D</i> , <b>2017</b> , 17, 427-434	3.4	5
33	A multifactorial study on nutritional status, binge eating and physical activity as main factors directly influencing body weight in Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2017</b> , 3, 17	9.7	5
32	Gender differences in age-related increase of asleep blood pressure. <i>Archives of Gerontology and Geriatrics</i> , <b>2010</b> , 50, 319-22	4	5
31	Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?. <i>International Journal of Neuroscience</i> , <b>2009</b> , 119, 2257-61	2	4
30	Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 995	4.1	4
29	Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. <i>Journal of Diabetes Research</i> , <b>2018</b> , 2018, 5601351	3.9	4
28	A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1046	4.1	3
27	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 509-522	1.1	3
26	Adverse drug reactions with Selegiline and Rasagiline compared to Levodopa and Ropinirole: A study in the French Pharmacovigilance Database. <i>Journal of the Neurological Sciences</i> , <b>2013</b> , 333, e129	3.2	3
25	Brief review: diurnal rhythms, obesity and educational achievement in South American cultures. <i>International Journal of Neuroscience</i> , <b>2009</b> , 119, 1091-104	2	3
24	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. <i>Movement Disorders</i> , <b>2021</b> , 36, 1704-1711	7	3
23	Cardiac autonomic activity predicts dominance in verbal over spatial reasoning tasks: results from a preliminary study. <i>Autonomic Neuroscience: Basic and Clinical</i> , <b>2012</b> , 167, 78-80	2.4	2
22	Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease. <i>Current Topics in Medicinal Chemistry</i> , <b>2015</b> , 15, 939-54	3	2
21	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 92, 53-58	3.6	2
20	The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene. <i>Frontiers in Synaptic Neuroscience</i> , <b>2021</b> , 13, 638519	3.5	2
19	Diagnosis and Management of Pain in Parkinson's Disease: A New Approach. <i>Drugs and Aging</i> , <b>2021</b> , 38, 559-577	4.7	2
18	Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study. <i>Clinical Drug Investigation</i> , <b>2016</b> , 36, 491-7	3.2	1
17	Orthostatic hypotension in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , <b>2013</b> , 3, 363-377.8	3.8	1

16	Bioequivalence of lamotrigine 50-mg tablets in healthy male volunteers: a randomized, single-dose, 2-period, 2-sequence crossover study. <i>Arzneimittelforschung</i> , <b>2012</b> , 62, 470-6		1
15	Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. <i>Journal of Neural Transmission</i> , <b>2020</b> , 127, 1607-1617	4.3	1
14	Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 86, 34-37	3.6	1
13	Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations. <i>Vaccines</i> , <b>2022</b> , 10, 722	5.3	1
12	Self-directed video versus instructor-based neonatal resuscitation training: a randomized controlled blinded non-inferiority multicenter international study. <i>Journal of Perinatology</i> , <b>2021</b> , 41, 1583-1589 <sup>0</sup>	3.1	
11	Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders. <i>Clinical Neuropharmacology</i> , <b>2018</b> , 41, 177-180	1.4	0
10	Clinical Effects of a 6-Month Treatment Course of Ibandronate, Vitamin D, and Calcium in Postmenopausal Women from Central America: Results of a Multinational, Prospective Pilot Study. <i>Integrative Medicine International</i> , <b>2016</b> , 3, 82-88	1.4	
9	Alteration of Biological Rhythms in Diseases of the Central Dopaminergic System: Focus on Parkinson's Disease <b>2016</b> , 91-114		
8	Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome. <i>Integrative Medicine International</i> , <b>2014</b> , 1, 32-43	1.4	
7	Assessment of Arterial Stiffness by 24-Hour Ambulatory Blood Pressure Monitoring in Nocturnal Hypertensive or Normotensive Subjects. <i>Integrative Medicine International</i> , <b>2015</b> , 1, 130-135	1.4	
6	On the diagnosis of pain in Parkinson disease: a mechanism-based approach.. <i>Pain</i> , <b>2022</b> , 163, e495		8
5	Genetic Factors Influencing the Development and Treatment of Cognitive Impairment and Psychosis in Parkinson's Disease <b>2019</b> , 359-370		
4	Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson's Disease. <i>Neuromethods</i> , <b>2021</b> , 177-190		0.4
3	Neuropsychiatric Symptoms Related to Cholinergic Deficits in Parkinson's Disease <b>2017</b> , 375-388		
2	Drug-Induced Movement Disorders in Elderly Patients <b>2014</b> , 87-115		
1	Drooling and dysphagia in Parkinson's disease. <i>International Review of Movement Disorders</i> , <b>2021</b> , 147-178		